抑制剂消灭和治疗获得的血友病A
Massimo Franchini1, Daniele Focosi2
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.
Expert review of hematology
|May 6, 2024
概括
获得性血友病A (AHA) 是一种罕见的自身免疫性出血障碍. 利图西马布在新诊断的AHA患者中显示出作为第一线治疗抑制剂消除的前景.
科学领域:
- 血液学 血液学 血液学
- 自身免疫性疾病 自身免疫性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 获得性血友病A (AHA) 是一种罕见的,危及生命的自身免疫性疾病.
- 具有针对凝血因子VIII (FVIII) 的自身抗体的特征.
- 可以是异常或由各种疾病引发,如癌症或感染.
研究的目的:
- 审查AHA的流行病学,临床,实验室和治疗特征.
- 专注于当前和创新的治疗方法,用于在AHA中消除抑制剂.
- 评估Rituximab作为一线治疗的潜力.
主要方法:
- 文学叙事审查. 文学叙事审查.
- 在Medline和PubMed数据库中进行全面的搜索,没有时间限制.
- 对AHA现有和新兴治疗选择的分析.
主要成果:
- 多种免疫抑制剂可用于AHA管理.
- 抗CD20单克隆抗体瑞图西马布是一种有前途的根除疗法.
- 初步数据表明,Rituximab作为新出现的AHA病例的第一线选择的疗效.
结论:
- 有效的AHA管理包括解决潜在原因,控制出血和消除抑制剂.
- 利图西马布代表了AHA治疗的重大进步,特别是在新诊断的患者中.
- 进一步的研究支持Rituximab在AHA治疗中的作用.
关键词:
获得的血友病A型FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII FVIII发生出血,出血.艾米奇祖马布 (Emicizumab) 是一种药物.抑制剂 抑制剂 抑制剂更多相关视频
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
14.1K
09:54Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
8.1K
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Retrovirus Life Cycles
45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
